« Return to News | Clinical Intelligence

FDA approves Gleevec for rare gastrointestinal cancer

Thursday, February 2, 2012 08:32 AM

The FDA has granted Gleevec (imatinib) regular approval for use in adult patients following surgical removal of CD117-positive gastrointestinal stromal tumors (GIST).

Gleevec, developed by Novartis, was originally granted accelerated approval for the treatment of advanced or metastatic GIST in 2002. In 2008, Gleevec received a subsequent accelerated approval for adjuvant use for the treatment of patients with GIST who had had potentially curative resection (surgical removal) of GIST tumors, but who were at increased risk for a recurrence.

The Gleevec label is being updated to include clinical data from a large, randomized clinical study comparing patients receiving the pill for 12 months versus those receiving it for 36 months. Patients treated with Gleevec for 36 months had a significantly prolonged survival rate and non-recurrence rate, compared to those receiving it for 12 months. At 60 months, 92% of patients who had received 36 months of Gleevec were alive compared to 82% of patients who received 12 months of Gleevec.

“The development of Gleevec over the past decade highlights the need to further study drugs after approval to truly characterize their benefits,” said Richard Pazdur, M.D., director of the office of hematology and oncology products in the FDA's Center for Drug Evaluation and Research.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.